Reply to: Appearances are often deceptive

Nuklearmedizin 2018; 57(04): 168-169
DOI: 10.1055/s-0038-1668503

Leserbrief/Letter

Georg Thieme Verlag

C. Boy

¹Klinik für Nuklearmedizin, Universitätsklinikum Essen

,

H. Lahner

²Klinik für Endokrinologie und Stoffwechselerkrankungen, ENETS Center of Excellence, Universitätsklinikum Essen

,

H.R. Maecke

³Klinik für Nuklearmedizin, Universitätsklinikum Freiburg

,

A. Bockisch

¹Klinik für Nuklearmedizin, Universitätsklinikum Essen

,

TD. Poeppel

¹Klinik für Nuklearmedizin, Universitätsklinikum Essen

References
1 Boy C, Poeppel T, Kotzerke J. et al. Somatostatin receptor PET/CT (SSTR-PET/CT). Nuklearmedizin 2018; 57: 4-17.
2 Hicks RJ, Kwekkeboom DJ, Krenning E. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology 2017; 105: 295-309.
3 Hope TA, Bergsland EK, Bozkurt MF. et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018; 59: 66-74.
4 Poeppel TD, Boy C, Bockisch A. et al. Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1). Nuklearmedizin 2015; 54: 1-11.
5 Rinke A, Wiedenmann B, Auernhammer C. et al. Practice guideline neuroendocrine tumors – AWMF-Reg. 021–27. Z Gastroenterol 2018; 56: 583-681.
6 Strosberg J, El-Haddad G, Wolin E. et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017; 12 (376) 125-135.
7 Sundin A, Arnold R, Baudin E. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. Neuroendocrinology 2017; 105: 212-244.